FBIO
Fortress Biotech, Inc.
$2.39
-0.42%
2026-05-08
About Fortress Biotech, Inc.
Fortress Biotech, Inc., together with its subsidiaries, operates as a biopharmaceutical company in the United States and internationally. The company offers Emrosi, a minocycline hydrochloride extended-release capsule for the treatment of rosacea; Qbrexza a medicated cloth towelette for the treatment of axillary hyperhidrosis; Accutane, an oral isotretinoin drug for the treatment of severe recalcitrant nodular acne; Amzeeq, a minocycline topical foam for the treatment of lesions of non-nodular moderate to severe acne vulgaris; Zilxi, a minocycline topical foam for the treatment of lesions of rosacea; Exelderm, an antifungal cream for topical use; Targadox, an oral doxycycline drug for the therapy of severe acne; Luxamend, a water-based emulsion for the treatment of superficial wounds, minor cuts or scrapes, dermal ulcers, donor sites, first and second-degree burns, and radiation dermatitis; and UNLOXCYT, a death-ligand 1 blocking antibody for the treatment of metastatic cutaneous squamous cell carcinoma. It also develops CUTX-101, a copper histidinate injection, which is in FDA approved stage for the treatment of Menkes disease; IV Tramadol, an intravenous formulation, which is in NDA/BLA filed stage for the treatment of post-operative acute pain; Dotinurad, a urate transporter inhibitor, which is in Phase III for the treatment of gout and chronic kidney diseases; CAEL-101, a light chain fibril-reactive monoclonal antibody, which is in Phase III for the treatment of amyloid light chain amyloidosis; and Triplex, a universal recombinant modified vaccinia ankara viral vector vaccine, which is in Phase II for the treatment of cytomegalovirus, anti-human immunodeficiency virus, non-hodgkin lymphoma, and acute lymphoblastic leukemia. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida.
Key Fundamentals
Forward P/E
-1.38
EPS (TTM)
$-0.07
ROE
-108.7%
Revenue Growth (YoY)
6.3%
Profit Margin
10.8%
Debt/Equity
108.09
Price/Book
1.52
Beta
1.16
Market Cap
$80.4M
Avg Volume (10D)
245K
Recent Breakout Signals
No recent breakout signals detected for FBIO.
Recent Price Range (60 Days)
60D High
$4.22
60D Low
$2.20
Avg Volume
669K
Latest Close
$2.39
Get breakout alerts for FBIO
Sign up for Breakout Scanner to receive daily notifications when FBIO triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial. No card required.
Fortress Biotech, Inc. (FBIO) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors FBIO daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. FBIO operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.